About
BRAINapt is an international adaptive clinical
trial platform dedicated to discovering and evaluating interventions to improve outcomes in critically ill adult patients with Traumatic Brain Injury (TBI)
Using an advanced Bayesian and adaptive methodology, we are pioneering new strategies for testing interventions for TBI care
Platform Trial Design
BRAINapt utilizes a perpetual, adaptive trial model to identify effective interventions for critically ill TBI patients. This approach enables the platform to efficiently and cost-effectively identify promising treatments and discontinue those that do not show efficacy
Our Focus
BRAINapt focusses on three primary domain families:
- Drugs
- Devices
- Other interventions (neither drugs nor devices)
These domain families encompass a variety of specific intervention types, with new domains added as innovative therapies and strategies become available
Our mission
Leveraging cutting-edge adaptive trial designs, BRAINapt aims to rapidly identify the most promising treatments and management approaches, ultimately improving outcomes for TBI patients
How BRAINapt Works
BRAINapt’s adaptive framework allows for the more efficient identification of effective treatments compared to traditional trial designs
Population: BRAINapt enrolls critically ill adult patients with acute moderate to severe TBI. Patients are randomized into one or more domains of interventions, receiving either the studied interventions or standard care
Outcome Measures: Various assessments are conducted, including long-term neurological recovery, quality of life, cognition, depression assessment, the need for organ support and adverse events
Our Team
BRAINapt brings together an international team of physicians, patients, stakeholders, researchers, methodologists and clinical trial experts from around the world. Each domain is led by a dedicated team committed to advancing the care and management of TBI
Domains
The BRAINapt domains focus on evaluating different strategies and their impact on outcomes in critically ill TBI patients
Our goal is to enhance recovery and improve overall health of TBI by exploring the effects of interventions
The first two domains to be studied in BRAINapt are the Beta-blocker domain and the Anticonvulsant Domain. Additionnal domains will be added over time.